Relay Therapeutics, Inc.

Relay Therapeutics is a clinical-stage precision medicines company focused on transforming drug discovery by enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its lead product candidate is RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor in clinical development for breast cancer, solid tumors, and vascular malformations. The company also develops aGal chaperone for Fabry disease, RLY-8161 targeting RAS family signaling proteins, and lirafugratinib (RLY-4008), a receptor tyrosine kinase for cancer treatment. Relay Therapeutics leverages computational modeling capabilities through a collaboration with D. E. Shaw Research to analyze protein motion and develop compounds. Additionally, it has partnerships with Elevar Therapeutics for RLY-4008 and Pfizer for RLY-2608 combinations.

Relay Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol RLAY. Its shares are traded in United States Dollars (USD). The company is headquartered in Cambridge, Massachusetts, United States, and its stock is accessible to investors through U.S. exchanges.

Relay Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage precision medicines company, it focuses on developing small molecule therapies for targeted oncology and genetic diseases. Biotechnology companies like Relay Therapeutics use biological processes and computational modeling to create drugs, often targeting specific molecular pathways involved in diseases such as cancer and genetic disorders.

Relay Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company was incorporated in 2015 and was formerly known as Allostery, Inc. before rebranding in December 2015. While its primary operations are in the U.S., its drug development programs target global markets for cancer and genetic diseases. The company collaborates with international partners such as Pfizer and Elevar Therapeutics to develop and commercialize its product candidates, indicating a reach beyond the U.S. market.

Relay Therapeutics' key product candidates include RLY-2608, a pan-mutant PI3Kα inhibitor for breast cancer, solid tumors, and vascular malformations; aGal chaperone for Fabry disease; RLY-8161 targeting RAS family proteins; and lirafugratinib (RLY-4008), a receptor tyrosine kinase for cancer. The company has a collaboration with D. E. Shaw Research to use computational modeling for protein motion analysis. It also has a license agreement with Elevar Therapeutics for the development and commercialization of RLY-4008, and an agreement with Pfizer to develop RLY-2608 in combination with fulvestrant and atirmociclib. These partnerships help advance its pipeline through shared expertise and resources.